Skip to main content
Top
Published in: Italian Journal of Pediatrics 1/2021

Open Access 01-12-2021 | Vaccination | Case report

Severe haemophilia A in a preterm girl with Turner syndrome: case report – a diagnostic and therapeutic challenge for a paediatrician (Part 2)

Authors: Berendt Agnieszka, Wójtowicz-Marzec Monika, Wysokińska Barbara, Kwaśniewska Anna

Published in: Italian Journal of Pediatrics | Issue 1/2021

Login to get access

Abstract

Background

Haemophilia A is an X-linked genetic condition which manifests itself mainly in male children in the first 2 years of life, during gross motor skill development. This disorder is rare in females. The clinical manifestation of severe haemophilia in preterm infants poses a great challenge to the therapeutic team. As extreme prematurity is linked to an increased risk of central nervous system or gastrointestinal bleeding, a well-informed and balanced treatment from the first days of life is crucial to prevent long-term damage.
Haemophilia is most commonly caused by inheriting defective genes, and can also be linked to skewed X inactivation and Turner syndrome.
The coincidental occurrence of haemophilia A and Turner syndrome is extremely rare, with only isolated cases described to date. Hence, a multidisciplinary approach is needed.

Case presentation

The authors report on a preterm girl (gestational age 28 weeks) diagnosed with haemophilia and Turner syndrome. The first manifestation of haemophilia was prolonged bleeding from injection sites on the second day of life. Indeterminate aPTT and factor VIII level < 1% confirmed the diagnosis of haemophilia A. Dysmorphic features which did not match the typical clinical picture of haemophilia, the female sex, and a negative paternal family history led to the diagnosis of Turner syndrome. While in hospital, the girl received multiple doses of recombinant factor VIII in response to prolonged bleedings from the injection sites and from a nodule on the girl’s head, and before and after retinal laser photocoagulation. No central nervous system or abdominal cavity bleeding was observed. The substitutive therapy was complicated by the development of factor VIII inhibitor (anti-factor VIII (FVIII) antibodies). Treatment was continued with recombinant factor VIIa. This article aims at demonstrating the complexity of the diagnostics and treatment of a preterm child with two genetic disorders.

Conclusions

Haemophilia should always be considered in the differential diagnosis of prolonged bleeding, even in patients with a negative family history. In the case of coinciding atypical phenotypic features, further diagnostics for another genetic disease are recommended. Infant care should follow current care standards, while considering certain individual features.
Literature
1.
go back to reference Negrier C. Severe hemophilia A. Orphanet encyclopedia https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=17872&Disease_Disease_Search_diseaseGroup=Hemophilia-A&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Severe-hemophilia-A&title=Severe%20hemophilia%20A&search=Disease_Search_Simple. Negrier C. Severe hemophilia A. Orphanet encyclopedia https://​www.​orpha.​net/​consor/​cgi-bin/​Disease_​Search.​php?​lng=​EN&​data_​id=​17872&​Disease_​Disease_​Search_​diseaseGroup=​Hemophilia-A&​Disease_​Disease_​Search_​diseaseType=​Pat&​Disease(s)/group%20of%20diseases=Severe-hemophilia-A&title=Severe%20hemophilia%20A&search=Disease_Search_Simple.
2.
8.
go back to reference Hemos IL. RecombiPlasTin 2G [package insert]. Bedford: Instrumentation Laboratory Company; 2019. Hemos IL. RecombiPlasTin 2G [package insert]. Bedford: Instrumentation Laboratory Company; 2019.
9.
go back to reference APTT. HemosIL APTT – SP (liquid) [package insert]. Bedford: Instrumentation Laboratory Company; 2019. APTT. HemosIL APTT – SP (liquid) [package insert]. Bedford: Instrumentation Laboratory Company; 2019.
10.
go back to reference Hemos IL. Factor VIII deficient plasma [package insert]. Bedford: Instrumentation Laboratory Company; 2017. Hemos IL. Factor VIII deficient plasma [package insert]. Bedford: Instrumentation Laboratory Company; 2017.
11.
go back to reference Hemos IL. Factor IX deficient plasma [package insert]. Bedford: Instrumentation Laboratory Company; 2008. Hemos IL. Factor IX deficient plasma [package insert]. Bedford: Instrumentation Laboratory Company; 2008.
12.
go back to reference Hemos IL. Factor XI deficient plasma [package insert]. Bedford: Instrumentation Laboratory Company; 2017. Hemos IL. Factor XI deficient plasma [package insert]. Bedford: Instrumentation Laboratory Company; 2017.
13.
go back to reference Hemos IL. Factor XI deficient plasma [package insert]. Bedford: Instrumentation Laboratory Company; 2018. Hemos IL. Factor XI deficient plasma [package insert]. Bedford: Instrumentation Laboratory Company; 2018.
14.
go back to reference Hemos IL. Von Willebrand Factor Antigen [package insert]. Bedford: Instrumentation Laboratory Company; 2016. Hemos IL. Von Willebrand Factor Antigen [package insert]. Bedford: Instrumentation Laboratory Company; 2016.
15.
go back to reference Hemos IL. Von Willebrand Factor Activity [package insert]. Bedford: Instrumentation Laboratory Company; 2018. Hemos IL. Von Willebrand Factor Activity [package insert]. Bedford: Instrumentation Laboratory Company; 2018.
17.
go back to reference Kooiman LM, Schroor EJ. A premature infant with increased bleeding tendency: what if the family history of bleeding disorders is negative? Ned Tijdschr Geneeskd. 2015;159:A9222 Dutch.PubMed Kooiman LM, Schroor EJ. A premature infant with increased bleeding tendency: what if the family history of bleeding disorders is negative? Ned Tijdschr Geneeskd. 2015;159:A9222 Dutch.PubMed
25.
go back to reference Laguna P, Klukowska A. Management of children with haemophilia complicated by inhibitor. J Transf Med. 2017;10(1):12–8 Polish. Laguna P, Klukowska A. Management of children with haemophilia complicated by inhibitor. J Transf Med. 2017;10(1):12–8 Polish.
28.
go back to reference Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia a. The Recombinate Study Group. Blood. 1994;83(9):2428–35.PubMed Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia a. The Recombinate Study Group. Blood. 1994;83(9):2428–35.PubMed
34.
go back to reference Polskie Towarzystwo Neonatologiczne. Standardy opieki medycznej nad noworodkiem w Polsce. 2nd ed. Warszawa: Media-Press Sp. z o. o; 2017:318. Polskie Towarzystwo Neonatologiczne. Standardy opieki medycznej nad noworodkiem w Polsce. 2nd ed. Warszawa: Media-Press Sp. z o. o; 2017:318.
Metadata
Title
Severe haemophilia A in a preterm girl with Turner syndrome: case report – a diagnostic and therapeutic challenge for a paediatrician (Part 2)
Authors
Berendt Agnieszka
Wójtowicz-Marzec Monika
Wysokińska Barbara
Kwaśniewska Anna
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Italian Journal of Pediatrics / Issue 1/2021
Electronic ISSN: 1824-7288
DOI
https://doi.org/10.1186/s13052-021-01103-7

Other articles of this Issue 1/2021

Italian Journal of Pediatrics 1/2021 Go to the issue